Vir Biotechnology, Inc.于2016年4月7日根据特拉华州法律注册成立。作为一家临床阶段的生物制药公司，VIR致力于增强免疫系统，以开发针对严重传染病和癌症的创新疗法。该公司的方法侧重于解决这些威胁逃避免疫防御的复杂机制。Vir的临床开发管道包括针对德尔塔型肝炎病毒和各种实体瘤的疗法，正在进行的临床项目和试验显示出新的护理标准的前景。该公司利用其专有技术平台DAISY和PRO-XTEN来优化抗体开发。凭借在免疫学、传染病和肿瘤学方面经验丰富的领导团队，VIR致力于通过其变革性疗法改变生活。
董事
名称
职位
Marianne De Backer
President, Chief Executive Officer and Director
Elliott Sigal
Independent Director
Janet Napolitano
Independent Director
Jeffrey S. Hatfield
Board Chair
Norbert Bischofberger
Independent Director
Ramy Farid
Independent Director
Robert More
Independent Director
股东
名称
职位
Marianne De Backer
President, Chief Executive Officer and Director
Jason O byrne
Executive Vice President and Chief Financial Officer
Mark Eisner
Executive Vice President and Chief Medical Officer
Vanina de Verneuil
Executive Vice President, General Counsel and Corporate Secretary